Initial Disclosure Clause Samples
The Initial Disclosure clause requires parties to provide certain key information or documents at the outset of a contractual relationship or legal proceeding. Typically, this involves sharing relevant facts, evidence, or materials that are essential for the other party to understand the case or agreement, such as financial records, witness lists, or pertinent contracts. By mandating early and transparent information exchange, this clause helps prevent surprises, streamlines the process, and ensures that both parties are adequately informed from the beginning.
Initial Disclosure. Promptly after the date hereof (and prior to, or simultaneously with the Company delivering a Request to the Investor hereunder), the Company shall file with the SEC a report on Form 8-K or such other appropriate form as determined by counsel to the Company, relating to the transactions contemplated by this Agreement and a preliminary Prospectus Supplement pursuant to Rule 424(b) of the Securities Act disclosing all information relating to the transaction contemplated hereby required to be disclosed therein and an updated Plan of Distribution, including, without limitation, the name of the Investor, the number of Shares being offered hereunder, the terms of the offering, the purchase price of the Shares, and other material terms of the offering, and any other information or disclosure necessary to register the transactions contemplated herein (collectively, the “Initial Disclosure”) and shall provide the Investor with 24 hours to review the Initial Disclosure prior to its filing. Promptly, and in any event no later than two days after each Purchase Notice Date, the Company shall file with the SEC a Prospectus Supplement pursuant to Rule 424(b) of the Securities Act disclosing all information relating to the particular Advance to be disclosed therein, including, without limitation, the number of Shares offered and the purchase price of the Shares, and other material terms of the particular offering, and any other information or disclosure necessary to register the Shares issued pursuant to such Advance.
Initial Disclosure. Within ten (10) days of execution of this Agreement Seller will deliver and communicate the Product Technology, Technical Data and Application Data to Buyer to enable Buyer to exercise its rights under the Agreement set forth in Section 1.3 (A) hereof. Seller will provide Buyer with sufficient technical support to ensure that Buyer may commence use of the Product and Enhanced Product pursuant to this Agreement.
Initial Disclosure. Promptly after the execution of the Initial Pre-Paid Purchase, Company shall file with the SEC a current report on Form 8-K or such other appropriate form as determined by counsel to Company (the “Current Report”), relating to the transactions contemplated by this Agreement disclosing all information relating to the transaction contemplated hereby required to be disclosed therein.
Initial Disclosure. Within four (4) business days after the execution of the Initial Pre-Paid Purchase, Company shall file with the SEC a current report on Form 6-K or such other appropriate form as determined by counsel to Company (the “Current Report”), relating to the transactions contemplated by this Agreement disclosing all information relating to the transaction contemplated hereby required to be disclosed therein.
Initial Disclosure. CSS Licensees shall be provided with Technical Specifications as specified in this Article 4. All Membership Categories will be provided with these Procedural Specifications. In addition, Technical Specifications provided to each CSS Licensee shall correspond with its Membership Category (or Categories), as follows.
Initial Disclosure. Within [***] days after expiration or termination of the Collaboration Term, Arcus shall deliver to Gilead, with respect to each Arcus Program, a written notice including instructions and credentials with which Gilead may access a Data Room containing the data and information (existing and available as of the date of Arcus’s notice) with respect to each Arcus Molecule.
Initial Disclosure. Within [***] following each Option Year, Codexis will discuss with Merck any Option Improvements which have come to be Controlled by Codexis during the applicable Option Year and which have been identified and are being practiced by Codexis in its own business operations, and will describe all such Option Improvements to Merck in sufficient detail to assist Merck in determining whether to exercise an Option with respect to such Option Improvements. Merck shall have [***] after receipt of the initial disclosure regarding such Option Improvements to request the disclosure of further information Controlled by Codexis with respect to such Option Improvements (“Option Evaluation Request”). All such disclosures, whether initial or subsequent, shall be considered the Information of Codexis.
Initial Disclosure. Within [***] days after the end of the Calendar Quarters ending June 30 and December 31:
(i) during the TT Term and, if GSK exercises the Option, during the Improvements TT Term, Codexis’ Alliance Manager shall disclose to GSK’s Alliance Manager [***] Codexis Core Technology Improvements by or on behalf of Codexis, or any Affiliate of Codexis and [***] corresponding Licensed Additional Codexis IP during the applicable half year period, if any; and
(ii) during the TT Term, Codexis’ Alliance Manager shall disclose to GSK’s Alliance Manager [***] Arising Codexis Enzyme Technology and/or Arising Codexis Process Technology by or on behalf of Codexis, or any Affiliate of Codexis and [***] corresponding Licensed Additional Codexis IP during the applicable half year period, if any.
Initial Disclosure. Within four (4) Trading Days of the Effective Date, Company shall file with the SEC a current report on Form 8-K or such other appropriate form as determined by counsel to Company (the “Current Report”), relating to the transactions contemplated by this Agreement disclosing all information relating to the transaction contemplated hereby required to be disclosed therein.
Initial Disclosure. Within [***] days after the end of the Calendar Quarters ending June 30 and December 31, during the TT Term, GSK shall disclose to Codexis’ Alliance Manager [***] Arising GSK Enzyme Technology and Arising GSK Process Technology, if any.